First Quarter of 2023 in Asia- Pacific Levocetirizine Dihydrochloride Prices
North America
Throughout the first quarter, the
Levocetirizine
Dihydrochloride Prices inclined in North America on account of a
continuous surge in inquiries from the pharmaceutical and healthcare sectors.
Moreover, Overall inflation eased with the start of 2023 and after a
significant prolonged labor shortage, owing to which the businesses in the US
increased employment in January, and wages rose. Following February, the prices
continued to display a similar trend and were recorded at USD 658000/MT CFR Los
Angeles. Towards the termination of Q1, as inquiries from the downstream sector
continued to rise, Inventories for Levocetirizine Dihydrochloride API remained
low among the market players, which compelled them to focus on raising their
shelves.
APAC
In the APAC region, Levocetirizine
Dihydrochloride price particularly in China, demonstrate an incremented
trend throughout the first quarter of 2023. In the month of January,
Levocetirizine Dihydrochloride prices inclined in China because of a significant
surge in domestic and international inquiries. The values rose at the same rate
as they depreciated in December. Ease in logistic charges and a continuous
surge in demand further supported the positive price trend of Levocetirizine
Di-hydrochloride during the month of February, and the costs noted during this
month were assembled at USD 618500/MT FOB Shanghai in China. With the end of
March, the prices remained in the northward direction, compelling the
manufacturers to raise their production activity and procure their shelves with
downstream Levocetirizine Di-hydrochloride stocks.
Europe
In the First quarter of 2023, the
market for Levocetirizine Di-Hydrochloride in Europe followed a similar path to
that in the Asia Pacific. The market trend began well until the end of March.
During the month of February, the prices achieved an assembly price of USD
672000/MT CFR Hamburg in Germany. Compared to the previous quarter, the
inquiries from the domestic market inclined at a steady rate. Market players
further focused on building their inventories for Levocetirizine
Dihydrochloride API to prevent their shortage. In addition to that, the trend
for this API at the end of the first quarter was supported by higher trade flow
and simpler logistic expenses when compared to the prior quarter.
ChemAnalyst tackles the primary
difficulty areas of the worldwide chemical, petroleum, pharmaceutical, and
petrochemical industries, empowering decision-makers to make informed
decisions. It examines and analyses geopolitical risks, environmental concerns,
raw material availability, supply chain functioning, and technological
disruption. It focuses on market volatility and guarantees that clients manage
obstacles and hazards effectively and efficiently. ChemAnalyst's primary
expertise has been data timeliness and accuracy, benefiting both local and
global industries by tuning in to real-time data points to execute
multibillion-dollar projects internationally.
Comments
Post a Comment